Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

NRX Pharmaceuticals (NRXP) Depreciation Expense (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Depreciation Expense for 2 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation Expense fell 303.03% to -$4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $10000.0 for FY2025, 0.0% changed from the prior year.
  • Depreciation Expense for Q4 2025 was -$4.0 million at NRX Pharmaceuticals, down from $2.0 million in the prior quarter.
  • The five-year high for Depreciation Expense was $2.0 million in Q3 2025, with the low at -$4.0 million in Q4 2025.